Ytterbium-169: calculated physical properties of a new radiation source for brachytherapy

Analytical HDR prostate brachytherapy planning with automatic catheter and isotope selection

BACKGROUND

High dose rate (HDR) brachytherapy is commonly used to treat prostate cancer. Existing HDR planning systems solve the dwell time problem for predetermined catheters and a single energy source.

PURPOSE

Additional degrees of freedom can be obtained by relaxing the catheters' pre-designation and introducing more source types, and may have a dosimetric benefit, particularly in improving conformality to spare the urethra. This study presents a novel analytical approach to solving the corresponding HDR planning problem.

METHODS

The catheter and dual-energy source selection problem was formulated as a constrained optimization problem with a non-convex group sparsity regularization. The optimization problem was solved using the fast-iterative shrinkage-thresholding algorithm (FISTA). Two isotopes were considered. The dose rates for the HDR 4140 Ytterbium (Yb-169) source and the Elekta Iridium (Ir-192) HDR Flexisource were modeled according to the TG-43U1 formalism and benchmarked accordingly. Twenty-two retrospective HDR prostate brachytherapy patients treated with Ir-192 were considered. An Ir-192 only (IRO), Yb-169 only (YBO), and dual-source (DS) plan with optimized catheter location was created for each patient with N catheters, where N is the number of catheters used in the clinically delivered plans. The DS plans jointly optimized Yb-169 and Ir-192 dwell times. All plans and the clinical plans were normalized to deliver a 15 Gy prescription (Rx) dose to 95% of the clinical treatment volume (CTV) and evaluated for the CTV D90%, V150%, and V200%, urethra D0.1cc and D1cc, bladder V75%, and rectum V75%. Dose-volume histograms (DVHs) were generated for each structure.

RESULTS

The DS plans ubiquitously selected Ir-192 as the only treatment source. IRO outperformed YBO in organ at risk (OARs) OAR sparing, reducing the urethra D0.1cc and D1cc by 0.98% (p = 2.22 ∗ 10 - 9 $p\ = \ 2.22*{10^{ - 9}}$ ) and 1.09% (p = 1.22 ∗ 10 - 10 $p\ = \ 1.22*{10^{ - 10}}$ ) of the Rx dose, respectively, and reducing the bladder and rectum V75% by 0.09 (p = 0.0023 $p\ = \ 0.0023$ ) and 0.13 cubic centimeters (cc) (p = 0.033 $p\ = \ 0.033$ ), respectively. The YBO plans delivered a more homogenous dose to the CTV, with a smaller V150% and V200% by 3.20 (p = 4.67 ∗ 10 - 10 $p\ = \ 4.67*{10^{ - 10}}$ ) and 1.91 cc (p = 5.79 ∗ 10 - 10 $p\ = \ 5.79*{10^{ - 10}}$ ), respectively, and a lower CTV D90% by 0.49% (p = 0.0056 $p\ = \ 0.0056$ ) of the prescription dose. The IRO plans reduce the urethral D1cc by 2.82% (p = 1.38 ∗ 10 - 4 $p\ = \ 1.38*{10^{ - 4}}$ ) of the Rx dose compared to the clinical plans, at the cost of increased bladder and rectal V75% by 0.57 (p = 0.0022 $p\ = \ 0.0022$ ) and 0.21 cc (p = 0.019 $p\ = \ 0.019$ ), respectively, and increased CTV V150% by a mean of 1.46 cc (p = 0.010 $p\ = \ 0.010$ ) and CTV D90% by an average of 1.40% of the Rx dose (p = 8.80 ∗ 10 - 8 $p\ = \ 8.80*{10^{ - 8}}$ ). While these differences are statistically significant, the clinical differences between the plans are minimal.

CONCLUSIONS

The proposed analytical HDR planning algorithm integrates catheter and isotope selection with dwell time optimization for varying clinical goals, including urethra sparing. The planning method can guide HDR implants and identify promising isotopes for specific HDR clinical goals, such as target conformality or OAR sparing.

Dosimetric impact of a robust optimization approach to mitigate effects from rotational uncertainty in prostate intensity-modulated brachytherapy

BACKGROUND

Intensity-modulated brachytherapy (IMBT) is an emerging technology for cancer treatment, in which radiation sources are shielded to shape the dose distribution. The rotatable shields provide an additional degree of freedom, but also introduce an additional, directional, type of uncertainty, compared to conventional high-dose-rate brachytherapy (HDR BT).

PURPOSE

We propose and evaluate a robust optimization approach to mitigate the effects of rotational uncertainty in the shields with respect to planning criteria.

METHODS

A previously suggested prototype for platinum-shielded prostate ¹⁶⁹ Yb-based dynamic IMBT is considered. We study a retrospective patient data set (anatomical contours and catheter placement) from two clinics, consisting of six patients that had previously undergone conventional ¹⁹² Ir HDR BT treatment. The Monte Carlo-based treatment planning software RapidBrachyMCTPS is used for dose calculations. In our computational experiments, we investigate systematic rotational shield errors of ±10° and ±20°, and the same systematic error is applied to all dwell positions in each scenario. This gives us three scenarios, one nominal and two with errors. The robust optimization approach finds a compromise between the average and worst-case scenario outcomes.

RESULTS

We compare dose plans obtained from standard models and their robust counterparts. With dwell times obtained from a linear penalty model (LPM), for 10° errors, the dose to urethra ( D 0.1 c c $D_{0.1cc}$ ) and rectum ( D 0.1 c c $D_{0.1cc}$ and D 1 c c $D_{1cc}$ ) increase with up to 5% and 7%, respectively, in the worst-case scenario, while with the robust counterpart, the corresponding increases were 3% and 3%. For all patients and all evaluated criteria, the worst-case scenario outcome with the robust approach had lower deviation compared to the standard model, without compromising target coverage. We also evaluated shield errors up to 20° and while the deviations increased to a large extent with the standard models, the robust models were capable of handling even such large errors.

CONCLUSIONS

We conclude that robust optimization can be used to mitigate the effects from rotational uncertainty and to ensure the treatment plan quality of IMBT.

Evaluation of dosimetric functions for a new 169 Yb HDR Brachytherapy Source

169 Yb has been recently used as an HDR brachytherapy source for cancer treatment. In this paper, dosimetric parameters of a new design of 169 Yb HDR brachytherapy source were determined by Monte Carlo (MC) method and film dosimetry. In this new source, the radioactive core has been encapsulated twice for safety purposes. The calculations of dosimetric parameters carried out using MC simulation in water and air phantom. In order to exclude photon contamination's cutoff energy, δ was set at 10 keV. TG-43U1 data dosimetric, including Sk , Λ, g(r), F(r, θ) was computed using outputs from the simulation and their statistical uncertainties were calculated. Dose distribution around the new prototype source in PMMA phantom in the framework of AAPM TG-43 and TG-55 recommendations was measured by Radiochromic film (RCF) Gafchromic EBT3. Obtained air kerma strength, Sk , and the dose rate constant, Λ, from simulation has a value of 1.03U ± 0.03 and 1.21 cGyh-1 U-1  ± 0.03, respectively. The radial dose function was calculated at radial distances between 0.5 and 10 cm with a maximum value of 1.15 ± 0.03 at 5-6 cm distances. The anisotropy functions for radial distances of 0.5-7 cm and angle distances 0° to180° were calculated. The dosimetric data of the new HDR 169 Yb source were compared with another reference source of 169 Yb-HDR and were found that has acceptable compatibility. In addition, the anisotropy function of the MC simulation and film dosimetry method at a distance of 1 cm from this source was obtained and a good agreement was found between the anisotropy results.

Monte Carlo dosimetric characterization of a new high dose rate 169 Yb brachytherapy source and independent verification using a multipoint plastic scintillator detector

PURPOSE

A prototype 169 Yb source was developed in combination with a dynamic rotating platinum shield system (AIM-Brachy) to deliver intensity modulated brachytherapy (IMBT). The purpose of this study was to evaluate the dosimetric characteristics of the bare/shielded 169 Yb source using Monte Carlo (MC) simulations and perform an independent dose verification using a dosimetry platform based on a multipoint plastic scintillator detector (mPSD).

METHODS

The TG-43U1 dosimetric parameters were calculated for the source model using RapidBrachyMCTPS. Real-time dose rate measurements were performed in a water tank for both the bare/shielded source using a custom remote afterloader. For each dwell position, the dose rate was independently measured by the three scintillators (BCF-10, BCF-12, and BCF-60). For the bare source, dose rate was measured at distances up to 3 cm away from the source over a range of 7 cm along the catheter. For the shielded source, measurements were performed with the mPSD placed at 1 cm from the source at four different azimuthal angles ( 0 ∘ , 9 0 ∘ , 18 0 ∘ , and 27 0 ∘ ).

RESULTS

The dosimetric parameters were tabulated for the source model. For the bare source, differences between measured and calculated along-away dose rates were generally below 5-10%. Along the transverse axis, deviations were, on average (range), 3.3% (0.6-6.2%) for BCF-10, 1.7% (0.9-2.9%) for BCF-12, and 2.2% (0.3-4.4%) for BCF-60. The maximum dose rate reduction due to shielding at a radial distance of 1 cm was 88.8 ± 1.2%, compared to 83.5 ± 0.5% as calculated by MC.

CONCLUSIONS

The dose distribution for the bare/shielded 169 Yb source was independently verified using mPSD with good agreement in regions close to the source. The 169 Yb source coupled with the partial-shielding system is an effective technique to deliver IMBT.

Needle-free cervical cancer treatment using helical multishield intracavitary rotating shield brachytherapy with the 169 Yb Isotope

PURPOSE

To assess the capability of an intracavitary ¹⁶⁹ Yb-based helical multishield rotating shield brachytherapy (RSBT) delivery system to treat cervical cancer. The proposed RSBT delivery system contains a pair of 1.25 mm thick platinum partial shields with 45° and 180° emission angles, which travel in a helical pattern within the applicator.

METHODS

A helically threaded tandem applicator with a 45° tandem curvature containing a helically threaded catheter was designed. A 0.6 mm diameter ¹⁶⁹ Yb source with a length of 10.5 mm was simulated. A 37-patient treatment planning study, based on Monte Carlo dose calculations using MCNP5, was conducted with high-risk clinical target volumes (HR-CTVs) of 41.2-192.8 cm³ (average ± standard deviation of 79.9 ± 35.8 cm³ ). All patients were assumed to receive 25 fractions of 1.8 Gy of external beam radiation therapy (EBRT) before receiving 5 fractions of high-dose-rate brachytherapy (HDR-BT). For each patient, ¹⁹² Ir-based intracavitary (IC) HDR-BT, ¹⁹² Ir-based intracavitary/interstitial (IC/IS) HDR-BT using a hybrid applicator with eight IS needles, and ¹⁶⁹ Yb-based RSBT plans were generated.

RESULTS

For the IC, IC/IS, and RSBT treatment plans, 38%, 84%, and 86% of the plans, respectively, met the planning goal of an HR-CTV D₉₀ (minimum dose to hottest 90%) of 85 Gy_EQD2 (α/β = 10 Gy). Median (25th percentile, 75th percentile) treatment times for IC, IC/IS, and RSBT were 11.71 (6.62, 15.40) min, 68.00 (45.02, 80.02) min, and 25.30 (13.87, 35.39) min, respectively. ¹⁹² Ir activities ranging from 159.1-370 GBq (4.3-10 Ci) and ¹⁶⁹ Yb activities ranging from 429.2-999 GBq (11.6-27 Ci) were used, which correspond to the same clinical ranges of dose rates at 1 cm off-source-axis in water. Extra needle insertion and planning time beyond that needed for intracavitary-only approaches was accounted for in the IC/IS treatment time calculations.

CONCLUSION

¹⁶⁹ Yb-based RSBT for cervical cancer met the HR-CTV D₉₀ goal of 85 Gy in a greater percentage of the patients considered than IC/IS (86% vs 84%, respectively) and can reduce overall treatment time relative to IC/IS. ¹⁶⁹ Yb-based RSBT could be used to replace IC/IS in instances where IC/IS treatment is not available, especially in instances when HR-CTV volumes are ≥30 cm³ .

Efficient 169 Yb high-dose-rate brachytherapy source production using reactivation

PURPOSE

To present and quantify the effectiveness of a method for the efficient production of ¹⁶⁹ Yb high-dose-rate brachytherapy sources with 27 Ci activity upon clinical delivery, which have about the same dose rate in water at 1 cm from the source center as 10 Ci ¹⁹² Ir sources.

MATERIALS

A theoretical framework for ¹⁶⁹ Yb source activation and reactivation using thermal neutrons in a research reactor and ¹⁶⁸ Yb-Yb₂ O₃ precursor is derived and benchmarked against published data. The model is dependent primarily on precursor ¹⁶⁸ Yb enrichment percentage, active source volume of the active element, and average thermal neutron flux within the active source.

RESULTS

Efficiency gains in ¹⁶⁹ Yb source production are achievable through reactivation, and the gains increase with active source volume. For an average thermal neutron flux within the active source of 1 × 10¹⁴  n cm^-2  s^-1 , increasing the active source volume from 1 to 3 mm³ decreased reactor-days needed to generate one clinic-year of ¹⁶⁹ Yb from 256 days yr^-1 to 59 days yr^-1 , and 82%-enriched precursor dropped from 80 mg yr^-1 to 21 mg yr^-1 . A resource reduction of 74%-77% is predicted for an active source volume increase from 1 to 3 mm³ .

CONCLUSIONS

Dramatic cost savings are achievable in ¹⁶⁹ Yb source production costs through reactivation if active sources larger than 1 mm³ are used.

Technical Note: Monte Carlo calculations of the AAPM TG-43 brachytherapy dosimetry parameters for a new titanium-encapsulated Yb-169 source

Due to a number of distinct advantages resulting from the relatively low energy gamma ray spectrum of Yb‐169, various designs of Yb‐169 sources have been developed over the years for brachytherapy applications. Lately, Yb‐169 has also been suggested as an effective and practical radioisotope option for a novel radiation treatment approach often known as gold nanoparticle‐aided radiation therapy (GNRT). In a recently published study, the current investigators used the Monte Carlo N‐Particle Version 5 (MCNP5) code to design a novel titanium‐encapsulated Yb‐169 source optimized for GNRT applications. In this study, the original MC source model was modified to accurately match the specifications of the manufactured Yb‐169 source. The modified MC model was then used to obtain a complete set of the AAPM TG‐43 parameters for the new titanium‐encapsulated Yb‐169 source. The MC‐calculated dose rate constant for this titanium‐encapsulated Yb‐169 source was 1.19 ± 0.03 cGy·h−1·U−1, indicating no significant change from the values reported for stainless steel‐encapsulated Yb‐169 sources. The source anisotropy and radial dose function for the new source were also found similar to those reported for the stainless steel‐encapsulated Yb‐169 sources. The current results suggest that the use of titanium, instead of stainless steel, to encapsulate the Yb‐169 core would not lead to any major change in the dosimetric characteristics of the Yb‐169 source. The results also show that the titanium encapsulation of the Yb‐169 source could be accomplished while meeting the design goals as described in the current investigators’ published MC optimization study for GNRT applications.

Comparison of the hypothetical (57)Co brachytherapy source with the (192)Ir source

Aim of the study

The ⁵⁷Co radioisotope has recently been proposed as a hypothetical brachytherapy source due to its high specific activity, appropriate half-life (272 days) and medium energy photons (114.17 keV on average). In this study, Task Group No. 43 dosimetric parameters were calculated and reported for a hypothetical ⁵⁷Co source.

Material and methods

A hypothetical ⁵⁷Co source was simulated in MCNPX, consisting of an active cylinder with 3.5 mm length and 0.6 mm radius encapsulated in a stainless steel capsule. Three photon energies were utilized (136 keV [10.68%], 122 keV [85.60%], 14 keV [9.16%]) for the ⁵⁷Co source. Air kerma strength, dose rate constant, radial dose function, anisotropy function, and isodose curves for the source were calculated and compared to the corresponding data for a ¹⁹²Ir source.

Results

The results are presented as tables and figures. Air kerma strength per 1 mCi activity for the ⁵⁷Co source was 0.46 cGyh^–1 cm 2 mCi^–1. The dose rate constant for the ⁵⁷Co source was determined to be 1.215 cGyh^–1U^–1. The radial dose function for the ⁵⁷Co source has an increasing trend due to multiple scattering of low energy photons. The anisotropy function for the ⁵⁷Co source at various distances from the source is more isotropic than the ¹⁹²Ir source.

Conclusions

The ⁵⁷Co source has advantages over ¹⁹²Ir due to its lower energy photons, longer half-life, higher dose rate constant and more isotropic anisotropic function. However, the ¹⁹²Ir source has a higher initial air kerma strength and more uniform radial dose function. These properties make ⁵⁷Co a suitable source for use in brachytherapy applications.

Design of an Yb-169 source optimized for gold nanoparticle-aided radiation therapy

PURPOSE

To find an optimum design of a new high-dose rate ytterbium (Yb)-169 brachytherapy source that would maximize the dose enhancement during gold nanoparticle-aided radiation therapy (GNRT), while meeting practical constraints for manufacturing a clinically relevant brachytherapy source.

METHODS

Four different Yb-169 source designs were considered in this investigation. The first three source models had a single encapsulation made of one of the following materials: aluminum, titanium, and stainless steel. The last source model adopted a dual encapsulation design with an inner aluminum capsule surrounding the Yb-core and an outer titanium capsule. Monte Carlo (MC) simulations using the Monte Carlo N-Particle code version 5 (MCNP5) were conducted initially to investigate the spectral changes caused by these four source designs and the associated variations in macroscopic dose enhancement across the tumor loaded with gold nanoparticles (GNPs) at 0.7% by weight. Subsequent MC simulations were performed using the EGSnrc and norec codes to determine the secondary electron spectra and microscopic dose enhancement as a result of irradiating the GNP-loaded tumor with the mcnp-calculated source spectra.

RESULTS

Effects of the source filter design were apparent in the current MC results. The intensity-weighted average energy of the Yb-169 source varied from 108.9 to 122.9 keV, as the source encapsulation material changed from aluminum to stainless steel. Accordingly, the macroscopic dose enhancement calculated at 1 cm away from the source changed from 51.0% to 45.3%. The sources encapsulated by titanium and aluminum/titanium combination showed similar levels of dose enhancement, 49.3% at 1 cm, and average energies of 113.0 and 112.3 keV, respectively. While the secondary electron spectra due to the investigated source designs appeared to look similar in general, some differences were noted especially in the low energy region (<50 keV) of the spectra suggesting the dependence of the photoelectron yield on the atomic number of source filter material, consistent with the macroscopic dose enhancement results. A similar trend was also shown in the so-called microscopic dose enhancement factor, for example, resulting in the maximum values of 138 and 119 for the titanium- and the stainless steel-encapsulated Yb-169 sources, respectively.

CONCLUSIONS

The current results consistently show that the dose enhancement achievable from the Yb-169 source is closely related with the atomic number (Z) of source encapsulation material. While the observed range of improvement in the dose enhancement may be considered moderate after factoring all uncertainties in the MC results, the current study provides a reasonable support for the encapsulation of the Yb-core with lower-Z materials than stainless steel, for GNRT applications. Overall, the titanium capsule design can be favored over the aluminum or dual aluminum/titanium capsule designs, due to its superior structural integrity and improved safety during manufacturing and clinical use.

Evaluation of (101)Rh as a brachytherapy source

PURPOSE

Recently a number of hypothetical sources have been proposed and evaluated for use in brachytherapy. In the present study, a hypothetical (101)Rh source with mean photon energy of 121.5 keV and half-life of 3.3 years, has been evaluated as an alternative to the existing high-dose-rate (HDR) sources. Dosimetric characteristics of this source model have been determined following the recommendation of the Task Group 43 (TG-43) of the American Association of the Physicist in Medicine (AAPM), and the results are compared with the published data for (57)Co source and Flexisource (192)Ir sources with similar geometries.

MATERIAL AND METHODS

MCNPX Monte Carlo code was used for simulation of the (101)Rh hypothetical HDR source design. Geometric design of this hypothetical source was considered to be similar to that of Flexisource (192)Ir source. Task group No. 43 dosimetric parameters, including air kerma strength per mCi, dose rate constant, radial dose function, and two dimensional (2D) anisotropy functions were calculated for the (101)Rh source through simulations.

RESULTS

Air kerma strength per activity and dose rate constant for the hypothetical (101)Rh source were 1.09 ± 0.01 U/mCi and 1.18 ± 0.08 cGy/(h.U), respectively. At distances beyond 1.0 cm in phantom, radial dose function for the hypothetical (101)Rh source is higher than that of (192)Ir. It has also similar 2D anisotropy functions to the Flexisource (192)Ir source.

CONCLUSIONS

(101)Rh is proposed as an alternative to the existing HDR sources for use in brachytherapy. This source provides medium energy photons, relatively long half-life, higher dose rate constant and radial dose function, and similar 2D anisotropy function to the Flexisource (192)Ir HDR source design. The longer half-life of the source reduces the frequency of the source exchange for the clinical environment.

Studies on the development of ¹⁶⁹Yb-brachytherapy seeds: New generation brachytherapy sources for the management of cancer

This paper describes development of (169)Yb-seeds by encapsulating 0.6-0.65 mm (ϕ) sized (169)Yb2O3 microspheres in titanium capsules. Microspheres synthesized by a sol-gel route were characterized by XRD, SEM/EDS and ICP-AES. Optimization of neutron irradiation was accomplished and (169)Yb-seeds up to 74 MBq of (169)Yb could be produced from natural Yb2O3 microspheres, which have the potential for use in prostate brachytherapy. A protocol to prepare (169)Yb-brachytherapy sources (2.96-3.7 TBq of (169)Yb) with the use of enriched targets was also formulated.

Dosimetric characterization of the GammaClip™ 169Yb low dose rate permanent implant brachytherapy source for the treatment of nonsmall cell lung cancer postwedge resection

PURPOSE

A novel (169)Yb low dose rate permanent implant brachytherapy source, the GammaClip™, was developed by Source Production & Equipment Co. (New Orleans, LA) which is designed similar to a surgical staple while delivering therapeutic radiation. In this report, the brachytherapy source was characterized in terms of "Dose calculation for photon-emitting brachytherapy sources with average energy higher than 50 keV: Report of the AAPM and ESTRO" by Perez-Calatayud et al. [Med. Phys. 39, 2904-2929 (2012)] using the updated AAPM Task Group Report No. 43 formalism.

METHODS

Monte Carlo calculations were performed using Monte Carlo N-Particle 5, version 1.6 in water and air, the in-air photon spectrum filtered to remove photon energies below 10 keV in accordance with TG-43U1 recommendations and previously reviewed (169)Yb energy cutoff levels [D. C. Medich, M. A. Tries, and J. M. Munro, "Monte Carlo characterization of an Ytterbium-169 high dose rate brachytherapy source with analysis of statistical uncertainty," Med. Phys. 33, 163-172 (2006)]. TG-43U1 dosimetric data, including SK, Ḋ(r,θ), Λ, gL(r), F(r, θ), φan(r), and φan were calculated along with their statistical uncertainties. Since the source is not axially symmetric, an additional set of calculations were performed to assess the resulting axial anisotropy.

RESULTS

The brachytherapy source's dose rate constant was calculated to be (1.22±0.03) cGy h(-1) U(-1). The uncertainty in the dose to water calculations, Ḋ(r,θ), was determined to be 2.5%, dominated by the uncertainties in the cross sections. The anisotropy constant, φan, was calculated to be 0.960±0.011 and was obtained by integrating the anisotropy factor between 1 and 10 cm using a weighting factor proportional to r(-2). The radial dose function was calculated at distances between 0.5 and 12 cm, with a maximum value of 1.20 at 5.15±0.03 cm. Radial dose values were fit to a fifth order polynomial and dual exponential regression. Since the source is not axially symmetric, angular Monte Carlo calculations were performed at 1 cm which determined that the maximum azimuthal anisotropy was less than 8%.

CONCLUSIONS

With a higher photon energy, shorter half-life and higher initial dose rate 169Yb is an interesting alternative to 125I for the treatment of nonsmall cell lung cancer.

Broad-beam transmission data for new brachytherapy sources, Tm-170 and Yb-169

The characteristics of the radionuclides (170)Tm and (169)Yb are highly interesting for their use as high dose-rate brachytherapy sources. The introduction of brachytherapy equipment containing these sources will lead to smaller required thicknesses of the materials used in radiation protection barriers compared with the use of conventional sources such as (192)Ir and (137)Cs. The purpose of this study is to determine the required thicknesses of protection material for the design of the protecting walls. Using the Monte Carlo method, transmission data were derived for broad-beam geometries through lead and concrete barriers, from which the first half value layer and tenth value layer are obtained. In addition, the dose reduction in a simulated patient was studied to determine whether transmission in the patient is a relevant factor in radiation protection calculations.

A dosimetric comparison of Yb169 versus Ir192 for HDR prostate brachytherapy

For the purpose of evaluating the use of 169Yb for prostate High Dose Rate brachytherapy (HDR), a hypothetical 169Yb source is assumed with the exact same design of the new microSelectron source replacing the 192Ir active core by pure 169Yb metal. Monte Carlo simulation is employed for the full dosimetric characterization of both sources and results are compared following the AAPM TG-43 dosimetric formalism. Monte Carlo calculated dosimetry results are incorporated in a commercially available treatment planning system (SWIFT), which features an inverse treatment planning option based on a multiobjective dose optimization engine. The quality of prostate HDR brachytherapy using the real 192Ir and hypothetical 169Yb source is compared in a comprehensive analysis of different prostate implants in terms of the multiobjective dose optimization solutions as well as treatment quality indices such as Dose Volume Histograms (DVH) and the Conformal Index (COIN). Given that scattering overcompensates for absorption in intermediate photon energies and distances in the range of interest to prostate HDR brachytherapy, 169Yb proves at least equivalent to 192Ir irrespective of prostate volume. This has to be evaluated in view of the shielding requirements for the 169Yb energies that are minimal relative to that for 192Ir.

Cross-section measurement of the 169Tm(p,n) reaction for the production of the therapeutic radionuclide 169Yb and comparison with its reactor-based generation

The radionuclide (169)Yb (T(1/2)=32.0 d) is potentially important for internal radiotherapy. It is generally produced using a nuclear reactor. In this work the possibility of its production at a cyclotron was investigated. A detailed determination of the excitation function of the (169)Tm(p,n)(169)Yb reaction was done over the proton energy range up to 45 MeV using the stacked-foil technique and high-resolution gamma-ray spectrometry. The integral yield of (169)Yb was calculated. Over the optimum energy range E(P)=16-->7 MeV the yield amounts to 1.5 MBq/micro Ah and is thus rather low. A comparison of this production route with the established (168)Yb(n,gamma)(169)Yb reaction at a nuclear reactor is given. The (169)Yb yield via the reactor route is by several orders of magnitude higher than by the cyclotron method. The latter procedure, however, leads to "no-carrier-added" product.

Accounting for high Z shields in brachytherapy using collapsed cone superposition for scatter dose calculation

Common clinical brachytherapy treatment planning algorithms perform at best one-dimensional corrections for high Z heterogeneities that will be inaccurate for intermediate energies (60-100 keV). The development of fast methods for a three-dimensional dose calculation to account for high Z materials in this energy range is important, e.g., to fully utilize the potential of patient individualized shields using isotopes such as 241Am and 169Yb. In this work we use the collapsed cone superposition algorithm to calculate the scatter dose contribution around partly lead-shielded point sources at 60, 100, and 350 keV. Methods to scale point kernels for water into kernels for high Z materials are derived. The scaling accounts for scattered photon spectral differences between materials and thus goes beyond the common density scaling approach. Compared to Monte Carlo simulations, the results of our algorithm yield agreements on the unshielded side to within 3% at 350 and 60 keV and to within 7% at 100 keV out to distances of 8 cm from the source. The effect of the shield in the center of the unshielded region is small at 350 keV but significant and occurs at short distances at 100 and 60 keV. At 60 keV, the shield causes a dose reduction of around 10%, 1 cm from the source on the unshielded side. At 100 keV, the reverse effect is seen, the insertion of shields leading to the total dose being increased by about 10% at 1 cm. That one-dimensional algorithms are incapable of predicting these changes shows the importance of accounting for the full three-dimensional geometry in correctly determining the scatter dose contribution.

Monte Carlo aided room scatter corrections in the air-kerma strength standardization of 169Yb and 60Co brachytherapy sources

For accurate evaluation of air-kerma strength, S(k), of 169Yb and 60Co brachytherapy sources, the present study reports Monte Carlo (MC) based corrections for (1) room scatter, and (2) departure from constant room scatter for rooms of various sizes. Correction for exponential attenuation of effective primary in air is also reported for the above sources. Values of S(k) per contained mCi, S(k)/A(c) predicted by MC calculations for 169Yb source (model X1267) with and without Ti K x-rays are 1.302 +/- 0.03% (this value is in excellent agreement with the published value reported by Piermattei et al) and 1.260 +/- 0.03% cGy cm2 h(-1) mCi(-1) respectively, and in the case of Cathetron 60Co source the value of S(k)/A(c) is 11.015 +/- 0.01% cGy cm2 h(-1) mCi(-1). It is observed that depending upon the position of the source with respect to the surrounding concrete scattering surfaces and set of d values, the assumption of constant room scatter has resulted in overestimation of S(k) that varied between 0.30% and 1.5% for the 169Yb source and only between 0.10% and 0.20% for the 60Co source.

Dosimetric parameters of three new solid core I-125 brachytherapy sources

Monte Carlo calculations and TLD measurements have been performed for the purpose of characterizing dosimetric properties of new commercially available brachytherapy sources. All sources tested consisted of a solid core, upon which a thin layer of 125I has been adsorbed, encased within a titanium housing. The PharmaSeed BT-125 source manufactured by Syncor is available in silver or palladium core configurations while the ADVANTAGE source from IsoAid has silver only. Dosimetric properties, including the dose rate constant, radial dose function, and anisotropy characteristics were determined according to the TG-43 protocol. Additionally, the geometry function was calculated exactly using Monte Carlo and compared with both the point and line source approximations. The 1999 NIST standard was followed in determining air kerma strength. Dose rate constants were calculated to be 0.955+/-0.005, 0.967+/-0.005, and 0.962+/-0.005 cGy h(-1) x U(-1) for the PharmaSeed BT-125-1, BT-125-2, and ADVANTAGE sources, respectively. TLD measurements were in excellent agreement with Monte Carlo calculations. Radial dose function, g(r), calculated to a distance of 10 cm, and anisotropy function, F(r,theta), calculated for radii from 0.5 to 7.0 cm, were similar among all source configurations. Anisotropy constants, phi(an), were calculated to be 0.941, 0.944, and 0.960 for the three sources, respectively. All dosimetric parameters were found to be in close agreement with previously published data for similar source configurations. The MCNP Monte Carlo code appears to be ideally suited to low energy dosimetry applications.

Absolute measurements of photon emission probabilities of 169Yb

A solution of 169Yb was absolutely standardized by the 4pi(EC,X)-gamma coincidence counting method and the result was used to obtain direct measurements of gamma-ray emission probabilities with a coaxial HPGe detector. The empirical relation proposed by (Vaño, F., Gonzalez, L., Gaeta R., Gonzalez, J.A., 1975. An empirical function which relates the slope of the Ge efficiency curves and the active volume Nucl. Instr. Meth. 123, 573) was tested using the gamma spectral response above 200 keV. The half-life of 169Yb was also measured with a 4pi gamma ionization chamber.

Dose rate constant and energy spectrum of interstitial brachytherapy sources

In the past two years, several new manufacturers have begun to market low-energy interstitial brachytherapy seeds containing 125I and 103Pd. Parallel to this development, the National Institute of Standards and Technology (NIST) has implemented a modification to the air-kerma strength (S(K)) standard for 125I seeds and has also established an S(K) standard for 103Pd seeds. These events have generated a considerable number of investigations on the determination of the dose rate constants (inverted V) of interstitial brachytherapy seeds. The aim of this work is to study the general properties underlying the determination of dose rate constant and to develop a simple method for a quick and accurate estimation of dose rate constant. As the dose rate constant of clinical seeds is defined at a fixed reference point, we postulated that dose rate constant may be calculated by treating the seed as an effective point source when the seed's source strength is specified in S(K) and its source characteristics are specified by the photon energy spectrum measured in air at the reference point. Using a semi-analytic approach, an analytic expression for dose rate constant was derived for point sources with known photon energy spectra. This approach enabled a systematic study of dose rate constant as a function of energy. Using the measured energy spectra, the calculated dose rate constant for 125I model 6711 and 6702 seeds and for 192Ir seed agreed with the AAPM recommended values within +/-1%. For the 103Pd model 200 seed, the agreement was 5% with a recently measured value (within the +/-7% experimental uncertainty) and was within 1% with the Monte Carlo simulations. The analytic expression for dose rate constant proposed here can be evaluated using a programmable calculator or a simple spreadsheet and it provides an efficient method for checking the measured dose rate constant for any interstitial brachytherapy seed once the energy spectrum of the seed is known.

Anisotropy functions for 169Yb brachytherapy seed models 5, 8 and X1267. An EGS4 Monte Carlo study

Anisotropy functions for 169Yb sources used in interstitial brachytherapy are investigated. A comprehensive study of several factors affecting the angular dose distribution around four 169Yb seed models (Amersham International) has been undertaken. Absolute dose rates around 169Yb seed models 5, 8a, 8b and X1267 have been estimated by means of the EGS4 Monte Carlo Simulation System. An updated cross section library (DLC-136/PHOTX), binding corrections for Compton scattering and water molecular form factors were included in the calculations. Following the formalism developed by the Interstitial Brachytherapy Collaborative Working Group, anisotropy functions, F(r, theta), have been calculated and compared with other Monte Carlo results and whenever possible with experimental data. Excellent agreement is found with other Monte Carlo calculations. Considering the large experimental errors reported, a fairly good coincidence has been achieved between experimental and Monte Carlo data for models 8a and 8b. For model X1267 large discrepancies with experiment are obtained. Monte Carlo calculations for all seed models showed model 5 to be the least anisotropic and models 8b and X1267 to be almost identical. Statistical fluctuations can be drastically reduced computationally, offering an efficient alternative to measured data. Our results have estimated uncertainties of 0.5%-1.0% within one standard deviation everywhere excluding the longitudinal source axis, where uncertainties are below 3% up to 5 cm, this accuracy being excellent for clinical calculations.

Results from the EUROMET action 410 concerning the decay data of 169Yb

An international comparison EUROMET, action No. 410, was organized with the objective of improving the knowledge of nuclear data for 169Yb decay. To determine the photon emission probabilities, the participants were asked to measure at least one of the quantities, activity per unit mass and/or photon emission rate per unit mass. In addition, the participants were requested to report the count rates observed with point source samples for an eventual coaxial-type germanium detector characterization. Eleven laboratories participated, giving one or more sets of results. In all, 34 sets of results were received, 17 for the activity measurement, 11 for the photon emission rate measurement and six for the detector characterization. Using the accurate activity value obtained from this exercise, it was possible to determine the emission probabilities of the main X- and gamma-rays with an uncertainty of 1-2% for the LX-rays, 1% for the KX-rays and < or =0.5% for the main gamma-rays. These data can be very useful for the calibration of so-called gamma-X ray detectors'. The measurement of 169Yb with type P or N coaxial structure detectors has also made possible an estimation of their diameters and volumes.

Radial dose functions for 103Pd, 125I, 169Yb and 192Ir brachytherapy sources: an EGS4 Monte Carlo study

Radial dose functions g(r) in water around 103Pd, 125I, 169Yb and 192Ir brachytherapy sources were estimated by means of the EGS4 simulation system and extensively compared with experimental as well as with theoretical results. The DLC-136/PHOTX cross section library, water molecular form factors, bound Compton scattering and Doppler broadening of the Compton-scattered photon energy were considered in the calculations. Use of the point source approach produces reasonably accurate values of the radial dose function only at distances beyond 0.5 cm for 103Pd sources. It is shown that binding corrections for Compton scattering have a negligible effect on radial dose function for 169Yb and 192Ir seeds and for 103Pd seeds under 5.0 cm from the source centre and for the 125I seed model 6702 under 8.0 cm. Beyond those limits there is an increasing influence of binding corrections on radial dose function for 103Pd and 125I sources. Results in solid water medium underestimate radial dose function for low-energy sources by as much as 6% for 103Pd and 2.5% for 125I already at 2 cm from source centre resulting in a direct underestimation of absolute dose rate values. It was found necessary to consider medium boundaries when comparing results for the radial dose function of 169Yb and 192Ir sources to avoid discrepancies due to the backscattering contribution in the phantom medium. Values of g(r) for all source types studied are presented. Uncertainties lie under 1% within one standard deviation.

Point kernels and superposition methods for scatter dose calculations in brachytherapy

Point kernels have been generated and applied for calculation of scatter dose distributions around monoenergetic point sources for photon energies ranging from 28 to 662 keV. Three different approaches for dose calculations have been compared: a single-kernel superposition method, a single-kernel superposition method where the point kernels are approximated as isotropic and a novel 'successive-scattering' superposition method for improved modelling of the dose from multiply scattered photons. An extended version of the EGS4 Monte Carlo code was used for generating the kernels and for benchmarking the absorbed dose distributions calculated with the superposition methods. It is shown that dose calculation by superposition at and below 100 keV can be simplified by using isotropic point kernels. Compared to the assumption of full in-scattering made by algorithms currently in clinical use, the single-kernel superposition method improves dose calculations in a half-phantom consisting of air and water. Further improvements are obtained using the successive-scattering superposition method, which reduces the overestimates of dose close to the phantom surface usually associated with kernel superposition methods at brachytherapy photon energies. It is also shown that scatter dose point kernels can be parametrized to biexponential functions, making them suitable for use with an effective implementation of the collapsed cone superposition algorithm.

Dose rate constants for 125I, 103Pd, 192Ir and 169Yb brachytherapy sources: an EGS4 Monte Carlo study

An exhaustive revision of dosimetry data for 192Ir, 125I, 103Pd and 169Yb brachytherapy sources has been performed by means of the EGS4 simulation system. The DLC-136/PHOTX cross section library, water molecular form factors, bound Compton scattering and Doppler broadening of the Compton-scattered photon energy were considered in the calculations. The absorbed dose rate per unit contained activity in a medium at 1 cm in water and air-kerma strength per unit contained activity for each seed model were calculated, allowing the dose rate constant (DRC) A to be estimated. The influence of the calibration procedure on source strength for low-energy brachytherapy seeds is discussed. Conversion factors for 125I and 103Pd seeds to obtain the dose rate in liquid water from the dose rate measured in a solid water phantom with a detector calibrated for dose to water were calculated. A theoretical estimate of the DRC for a 103Pd model 200 seed equal to 0.669 +/- 0.002 cGy h(-1) U(-1) is obtained. Comparison of obtained DRCs with measured and calculated published results shows agreement within 1.5% for 192Ir, 169Yb and 125I sources.

The clinical radiobiology of brachytherapy

The unique geometrical features of brachytherapy, together with the wide variety of temporal patterns of dose delivery, result in important interactions between physics and radiobiology. These interactions exert a major influence on the way in which brachytherapy treatments should be evaluated, both in absolute and comparative terms. This article reviews the main physical and radiobiological aspects of brachytherapy and considers examples of their influence on specific types of treatment. The issues relating to the optimization of high dose rate brachytherapy are presented, together with the implications of multiphasic repair kinetics for low dose-rate and pulsed high dose rate brachytherapy. The opportunities for application of radiobiological principles to improve various brachytherapy techniques, together with the integration of brachytherapy with teletherapy, are also outlined. Equations for the numerical evaluation of brachytherapy treatments are presented in the Appendices.

Analytical approach to heterogeneity correction factor calculation for brachytherapy

In brachytherapy treatment planning, the effects of tissue and applicator heterogeneities are commonly neglected due to lack of accurate, general, and fast three-dimensional (3D) dose-computational algorithms. A novel approach, based on analytical calculation of scattered photon fluxes inside and around a disk-shaped heterogeneity, has been developed for use in the three-dimensional scatter-subtraction algorithm. Specifically, our model predicts the central-ray dose distribution for a collimated photon isotropic source or brachytherapy "minibeam" in the presence of a slab of heterogeneous material. The model accounts for the lateral dimensions, location, composition, density, and thickness of the heterogeneity using precalculated scatter-to-primary ratios (SPRs) for the corresponding homogeneous problem. The model is applicable to the entire brachytherapy energy range (25 to 662 keV) and to a broad range of materials having atomic numbers of 13 to 82, densities of 2.7 g.cm-3 (Al) to 21.45 g.cm-3 (Pt) and thicknesses up to 1 mean free path. For this range of heterogeneous materials, the heterogeneity correction factors (HCFs) vary from 0.09 to 0.75. The model underestimates HCF when multiple scattering prevails and overestimates HCF when absorption dominates. However, the analytic model agrees with Monte Carlo photon transport (MCPT) benchmark calculations within 1.8% to 10% for 125I, 169Yb, 192Ir, and 137Cs for a wide variety of materials, with the exception of Ag. For 125I shielded by Ag, where the mean discrepancy can exceed 25%, the error is due to K-edge characteristic x rays originating within the heterogeneity. The proposed approach provides reductions in CPU time required of 5 x 10(4)-10(5) and 100 in comparison with direct MCPT simulation and 1D numerical integration, respectively. The limitations of model applicability, as determined by the physical properties of heterogeneity material and accuracy required, are also discussed.

Current issues in techniques of prostate brachytherapy

Adenocarcinoma of the prostate is the most common malignancy diagnosed among men in the United States today. Brachytherapy permits conformal radiotherapy and dose escalation, and it offers the convenience of a single-day outpatient procedure which is very attractive to patients with a busy life-style. The reported potency preservation rates with brachytherapy are superior to both external beam radiation therapy (EBRT) and surgery. The older retropubic techniques have been replaced by ultrasound or CT-guided transperineal techniques. Prostate brachytherapy may be temporary or permanent, and the planning techniques for either approach are similar. This review briefly discusses the advantages and limitations of each. Temporary techniques may be used with low dose rate or high dose rate applications. The basic steps include assessing prostate volume by any diagnostic modality (CT or ultrasonography), determining total activity needed to encompass the gland and deliver the appropriate minimum peripheral dose, and determining the pattern of placement of the seeds within the gland. Preplanning may be done either by ultrasound or by CT. The operative technique requires the visualization of the prostate in three dimensions and is performed using combination of ultrasound and fluoroscopy or fluoroscopy in two axes. The New York Hospital technique employs CT-based preplanning along with ultrasound and fluoroscopy during the operative procedure. Special circumstances that necessitate neoadjuvant hormonal therapy include interference from the pubic arch and large volume glands. An analysis of patients with stage T2a disease treated at the New York Hospital-Queens, from 1990-1995, reveals an actuarial clinical freedom from relapse of 79% at 5 years and a 5-year biochemical freedom from relapse of 64% which is comparable to that reported for similar risk groups of disease by other centers. Potency is preserved in greater than 80% of patients in our series. Patient selection criteria include the pre-treatment prostate-specific antigen (PSA) level, tumor grade (Gleason), stage of disease, and presence or absence of bilateral positive biopsies and/or perineural invasion. Based on our review of the literature and our clinical results, we have divided patients with prostate cancer into good, intermediate and poor risk groups. We recommend brachytherapy as the sole procedure for good risk patients, and a combination of external beam radiation therapy (EBRT) and brachytherapy for the intermediate risk group. Future avenues for research include a search for improved imaging techniques and possibly newer isotopes.

Analysis of the radiobiology of ytterbium-169 and iodine-125 permanent brachytherapy implants

Recently, Yb-169 has been considered as a potential replacement for I-125 and Pd-103 in permanent implants. In spite of the uncertainties in the parameters necessary for an accurate radiobiological modelling, the linear quadratic model can be useful in the comparative evaluation of the radiotherapeutic merit of similar implants. In order to find out if a Yb-169 permanent implant can be made biologically 'equivalent' to an I-125 implant, we studied the dependence of local control on the tumour cell radiosensitivity and on the balance between the rate of tumour cell killing and tumour cell proliferation, for rapidly and slowly proliferating tumours. The extrapolated response dose (ERD) has been calculated for tumour and late reacting normal tissue for both types of implants and the possible biological restrictions due to the normal tissue tolerance have been discussed. Our theoretical analysis is consistent with the clinical results published for I-125 permanent implants in prostate tumours and meningiomas. It predicts that Yb-169, which has only recently been used in human tumours, can provide comparable tumour control for permanent implants in slowly proliferating tumours with an initial dose rate of 13 cGy h-1. Control might be extended to rapidly proliferating tumours by increasing the initial dose rate within a range consistent with an acceptable level of normal tissue late reaction.

Applications of the Italian protocol for the calibration of brachytherapy sources

The Associazione Italianà di Fisica Biomedica (AIFB; Italian Association of Biomedical Physics) has adopted the Italian protocol for the calibration of brachytherapy sources. The AIFB protocol allows measurements of the reference air kerma rate, Kr, within 1.7% (1 sigma). To measure Kr the AIFB protocol has identified a direct and an indirect procedure. The direct procedure is based on the use of spherical or cylindrical ionization chambers as local reference dosimeters positioned along the transverse bisector axis of the source. Once the source is specified by a Kr value, this can be used to calibrate a field instrument, such as a well-type ionization chamber, for further source calibrations by means of an indirect procedure. This paper reports the results obtained by the Physics Laboratory of the Università Cattolica del S Cuore (PL-UCSC), in terms of Kr calibration of five types of source, 169Yb, 192Ir and 137Cs. The role of the Kr determination for a brachytherapy source has been underlined when a new source such as the 169Yb seed model X1267 has been proposed for clinical use. The Kr values for 137Cs spherical sources differed by 5% from the vendor's mean value. The five types of source calibrated in terms of Kr were used to obtain the calibration factor. NKrsource, of an HDR-1000 well-type ionization chamber.

Dosimetry of 169 Yb seed model X1267

Unlike previous brachytherapy sources a number of published studies have been addressed to the dosimetry of 169 Yb seeds, manufactured in several prototypes, before widespread clinical use has been made. Discrepancies seen in the dosimetry obtained for ytterbium seed prototypes appear to be related to inconsistency and non-reproducibility in the vendor's calibration procedure to determine contained activity. Av. The comparison of 169 Yb seed dosimetries demonstrates a need for more accurate implementation of calibration procedures to determine the air kerma rate for the definitive 169 Yb seed design. This paper reports an experimental procedure to determine the reference air kerma rate, Kr (mu Gy h-1), defined as the kerma rate at 1 m along the source transverse axis in free space for the new 169 Yb seed, model X1267. A mean value of the ratio Kr/Av = 1.53 mu Gy h-1 mCi-1 was obtained from determining the Kr value of eleven seeds. Since this ratio is only 3% less than the air kerma rate constant for the 169 Yb point source, (gamma delta)k = 1.58 mu Gy h-1 m2 mCi-1, this means that the Av is closer to an apparent activity than a contained activity, Ac. A Monte Carlo simulation to determine the ratio between reference air kerma rate and the contained activity gave Kr/Ac = 1.33 mu Gy h-1 mCi-1. For the dose rate constant in water we obtained DKr (1, pi/2) = 1.20 +/- 0.05 cGy h-1 (mu Gy h-1)-1, using calibrated thermoluminescent dosimeters (TLDs) and DKr (1, pi/2) = 1.21 +/- 0.03 cGy h-1 (mu Gy h-1)-1 by Monte Carlo simulation. TLDs were used both to determine the radial dose distribution along the seed transverse axis and to calibrate GAFChromic films to obtain the two-dimensional dose distribution around the seed.

A secondary air kerma strength standard for Yb-169 interstitial brachytherapy sources

Ytterbium-169 (169Yb) is a promising new intermediate low-energy isotope for interstitial implantation. To date, no air kerma strength (SK) standard for this source exists that can serve as a sound foundation for comparing various dose measurements and theoretical calculations. We have solved this problem by adapting the free air measurement technique of Goetsch et al, originally developed for 192Ir. Using a 100 cm3 spherical ion chamber with NIST traceable external beam calibrations in a free air geometry, we have measured the air kerma strength of six different source batches (two type 6 batches, three type 8 batches, and one experimental high-intensity source). Room scatter corrections, derived from an empirical fit to the data (following Goetsch et al) and/or directly by Monte Carlo simulation, yielded identical results with a reproducibility of 1%. The ratio [SK/Avendor] of measured SK to the vendor's contained activity assay averaged 1.554 cGy cm2 mCi-1 h-1 (0.0420 microGy m2 MBq-1 h-1), in conflict with the expected value of 1.34 (0.0362), derived from Monte Carlo calculations. The measured [SK/Avendor] for the type 8 seeds varies by as much as 10% whereas the SK/dose calibrator reading ratio varies by no more than 0.3%, suggesting that the reproducibility of Avendor is relatively poor. These discrepancies may help explain the variation (as large as 28%) in published dose rate constants for 169Yb.

Effect of tumour shrinkage on the biological effectiveness of permanent brachytherapy implants

A tumour shrinkage factor is incorporated into previously derived linear-quadratic (LQ) formulae which allowed radiobiological assessment of the efficacy of permanently implanted radionuclides. The new formulations relate the biologically effective dose (BED) to radionuclide half-life, recovery half-life, tumour radiosensitivity, potential doubling time and linear shrinkage rate. Specific attention has been given to the following radionuclides: gold-198 (half-life, 2.7 days), palladium-103 (half-life, 17 days), ytterbium-169 (half-life, 32 days) and iodine-125 (half-life, 60 days). For each nuclide the log cell kill resulting from typically prescribed doses was calculated for a range of tumour clonogen doubling times at various radiosensitivities and linear shrinkage rates. It is shown that even relatively modest shrinkage rates are capable of enhancing the clinical potential of the longer-lived nuclides. However, even though the effect of tumour shrinkage is minimal in the case of gold-198, for fast growing and/or insensitive tumours there are fewer radiobiological uncertainties associated with the use of this nuclide. The revised equations may also have applications in certain types of biologically targeted radiotherapy.

Dosimetric characteristics, air-kerma strength calibration and verification of Monte Carlo simulation for a new Ytterbium-169 brachytherapy source

PURPOSE

Ytterbium-169 (169Yb) is a promising new isotope for brachytherapy with a half life of 32 days and an average photon energy of 93 KeV. It has an Ir-192-equivalent dose distribution in water but a much smaller half-value layer in lead (0.2 mm), affording improved radiation protection and customized shielding of dose-limiting anatomic structures. The goals of this study are to: (a) experimentally validate Monte Carlo photon transport dose-rate calculations for this energy range, (b) to develop a secondary air-kerma strength standard for 169Yb, and (c) to present essential treatment planning data including the transverse-axis dose-rate distribution and dose correction factors for a number of local shielding materials.

METHODS AND MATERIALS

Several interstitial 169Yb sources (type 6) and an experimental high dose-rate source were made available for this study. Monte-Carlo photon-transport (MCPT) simulations, based upon validated geometric models of source structure, were used to calculate dose rates in water. To verify MCPT predictions, the transverse-axis dose distribution in homogeneous water medium was measured using a silicon-diode detector. For use in designing shielded applicators, heterogeneity correction factors (HCF) arising from small cylindrical heterogeneities of lead, aluminum, titanium, steel and air were measured in a water medium. Finally, to provide a sound experimental basis for comparing experimental and theoretical dose-rate distributions, the air-kerma strength of the sources was measured using a calibrated ion chamber. To eliminate the influence of measurement artifacts on the comparison of theory and measurement, simulated detector readings were compared directly to measured diode readings. The final data are presented in the format endorsed by the Interstitial Collaborative Working Group.

RESULTS

The in-air calibration revealed that the air-kerma strength per unit activity (mCi), as quoted by the vendor, varied from 1.30 to 1.57 cGy.cm2/mCi.h depending on seed design. The maximum difference between measured and MCPT-simulated absolute diode readings on the transverse axis was less than 2%, indicating that MCPT accurately predicts dose rate in medium for brachytherapy sources in this energy range. Comparison of measured and simulated HCFs for each of the 16 different cylindrical heterogeneities demonstrated 1-3% agreement. The HCFs vary by as much as 200% with respect to distance and by as much as 48% as a function of disk diameter, showing that HCF is strongly dependent on heterogeneity location and lateral dimensions as well as thickness. The dose-rate constant for water medium was found to be 1.225 cGy/h per kerma unit air-strength and 1.962 cGy/h per unit mCi as measured by the vendor.

CONCLUSION

Monte Carlo simulation is an accurate and powerful tool for dosimetric characterization of brachytherapy sources in this energy range. Thin lead foils produce shielding factors comparable to standard shielded applicators for 137Cs. Meaningful theoretical absolute dose calculations in brachytherapy require accurately implemented air-kerma strength standards.

The relative biological effectiveness of ytterbium-169 for low dose rate irradiation of cultured mammalian cells

PURPOSE

An important step in the development of 169Yb as a new brachytherapy source is to determine its biological effectiveness relative to other commonly used radioisotopes. The purpose of this paper is to determine the relative biological effectiveness of 169Yb, with respect to 60Co, for a range of low dose rates.

METHOD AND MATERIALS

The relative biological effectiveness of photon radiation from encapsulated 169Yb was determined by exposing Chinese hamster ovary cells, in exponential growth, to graded doses of radiation from either 169Yb or 60Co. Clonogenic cell survival was determined for continuous low dose rates ranging from 6.5 cGy/hr to 52 cGy/hr.

RESULTS

The relative biological effectiveness of 169Yb, with respect to 60Co, was determined to be 1.2 +/- 0.3 and did not vary significantly over the dose-rate range from 13 cGy/hr to 50 cGy/hr. An inverse dose-rate effect was observed, but only for 60Co irradiation at 8.9 cGy/hr. Therefore, relative biological effectiveness values could not be determined reliably for dose rates less than 13 cGy/hr.

CONCLUSIONS

We have established that 169Yb is approximately 20% more effective than 60Co in vitro. It is hoped that this study will guide the introduction of 169Yb into clinical brachytherapy practice.